Our Mission
Contribute to the health and future
of cancer patients and their families
through the development of novel biologically targeted radiation therapy
The two overlapping hexagons represent “BNCT” and “nanotechnology,” respectively, and their overlapping symbolizes the image of shining light.
We aim to bring new possibilities to cancer treatment through this therapy born from the encounter of BNCT and nanotechnology, and to serve as a reliable light for cancer patients and their families.
RadioNano Therapeutics Inc.
Headquarters: 36-1 Yoshidahonmachi, Sakyo-ku, Kyoto, JAPAN 606-8501
Establishment: April 1, 2024
Capital： 236,977,500 JPY
Representative: CEO Masatoshi Chiba
Stockholders： Kyoto University Innovation Capital Corporation, Mitsubishi UFJ Capital Co. Ltd., DBJ Capital Co. Ltd., Japan Science and Technology Agency.
Members
CEO
Masatoshi Chiba, PhD
Experience in pharma for over 35 years.
Expertise in DDS and CMC.
Management of EU Subsidiaries as CEO
Independent Director
Prof. Naoki Komatsu, PhD
Graduate School of Human and Environmental Studies,
Kyoto University
Scientific Advisory Committee
Minoru Suzuki, MD PhD
Institute for Integrated Radiation and Nuclear Science,
Kyoto University
CBO/COO
Hiroshi Kawai, PhD
Experience in pharma for over 30 years.
Expertise in Pharmacology and BD
Management of US Subsidiaries as VP
Management of biotech venture as CEO
Independent Director
Hiroyuki Ueno, PhD
Kyoto University Innovation Capital Co., Ltd. (Kyoto iCAP)